Status:
COMPLETED
To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients
Lead Sponsor:
Linical Korea
Collaborating Sponsors:
Astellas Pharma Korea, Inc.
National Cancer Center, Korea
Conditions:
Liver Transplantation
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
This study's objective is to evaluate the incidence rate of acute rejection reactions after 24 weeks treatment with ADVAGRAF® following 3 months treatment with tacrolimus in new liver transplant recip...
Detailed Description
This is single center,open-label study with ADVAGRAF® Primary endpoint is Incidence rate of biopsy confirmed acute rejection reactions within 24 weeks following conversion+ Incidence rate of acute rej...
Eligibility Criteria
Inclusion
- When the Subjects agree informed consent form, Subject should be More than 20 years of age
- Those who are transplanated liver at a minimum of 10 weeks or Maximum of 14 weeks of baseline
- Average of tacrorimus trough level is 3-10 ng/mL from transplanted date to before baseline.
- Female subjects of child bearing potential must have a negative urine or serum pregnancy test prior to enrolment and at the end of study and must agree to practice effective birth control during the study.(The oral contraceptive pill is not allowed to take a female subject) ⑤Subjects are stable clinically in the opinion of the investigator. ⑥Subjects capable of understanding the purpose and risks of the study, having been fully informed and has given written informed consent to participate in the study
Exclusion
- Subjects having previously received an organ transplant excluding liver transplant. Or Subjects receiving an auxiliary graft or in whom a bio-artificial liver(cell system) has been used.
- Acute rejection from transplanted date to before baseline
- Subjects diagnosed new malignant tumor after liver transplantation, with the exception of basalioma or squamous cell carcinoma of the skin that has been treated successfully.
- Subjects allergic to tacrolimus or investigational product.
- Subjects are unstable clinically state in the opinion of the investigator.
- Subjects with any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator.
- ⑦Subjects participating or having participated in another clinical trial and/or those taking or having taken an investigational / non-registered drug in the past 28 days.
- ⑧Subjects taking forbidden concomitant medications or within 28 days prior to enroll.
- Subjects who are pregnant or breast-feeding mother.
- ⑩Subjects known to be HIV positive.
- ⑪Subjects unlikely to comply with the visits scheduled in the protocol.
- ⑫Subjects with renal dysfunction on the investigator's point of view or serum creatinine \> 1.6mg/dL or GFR(MDRD)\<30mL/min in the baseline.
- ⑬Hepatic dysfunction: rising more than triple the normal range of SGPT/ALT and/or SGOT/AST and/or bilirubin, hepatic cirrhosis
Key Trial Info
Start Date :
July 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 14 2017
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT04761731
Start Date
July 1 2015
End Date
December 14 2017
Last Update
February 21 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.